Posted by Michael Wonder on 27 Jun 2025
Sephience (sepiapterin) granted marketing authorisation by the European Commission for the treatment of children and adults living with phenylketonuria
23 June 2025 - Launch to be initiated in Germany.
PTC Therapeutics today announced that Sephience (sepiapterin) was granted marketing authorisation by the European Commission for the treatment of children and adults living with phenylketonuria.
